Immune System Key Ltd.

Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
It is engaged in discovery and development of innovative treatments for malignant and autoimmune diseases with strong unmet needs. ISK’s assets are based on novel human secreted peptides, which were discovered by the founders. ISK’s lead compound is NerofeTM. NerofeTM was granted by the FDA with orphan drug status for AML treatment and currently is in phase IIa development stage. The company holds 3 worldwide patents on the molecule and applications.

LATEST NEWS

  • ISK at Sachs conference

ISK attended the 2019 Sachs conference in Zurich

05 Mar|Comments Off on ISK attended the 2019 Sachs conference in Zurich

  • Rosenblatt, Joseph D, M.D

Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory board

25 Feb|Comments Off on Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory board

Prof. Joseph D Rosenblatt
Joseph D Rosenblatt is Professor of Medicine, Microbiology and Immmunology at the University of Miami Miller School of Medicine , and currently serves as the William Harrington Professor of Hematology and Chief of the University of Miami Division of Hematology.
He previously served as chief of the combined Division of Hematology – Oncology from 2001-2017, when Hematology became a separate Division. Rosenblatt also currently serves as Associate Director for Faculty Development in the Sylvester Comprehensive Cancer Center and previously served as Interim Director of the Sylvester Comprehensive Cancer Center from 2010-2012. From 2001 -2017 he served as Associate Director for Clinical and Translational Research within the Sylvester Comprehensive Cancer Center.
Dr. Rosenblatt joined UM/Sylvester in September 2001 from the

  • download

Nerofe has received a new US patent for metastatic cancer treatment

21 Nov|Comments Off on Nerofe has received a new US patent for metastatic cancer treatment

  • rabin medical center

Phase2a Nerofe study has begun in Rabin and Kaplan medical centers

21 Sep|Comments Off on Phase2a Nerofe study has begun in Rabin and Kaplan medical centers

Phase2a Nerofe study has begun in Rabin and Kaplan medical centers

  • _A0A0227

PMWC 2018 conference – New Technology Presented

04 Feb|Comments Off on PMWC 2018 conference – New Technology Presented

At  PMWC 2018 conference Dr. Yoram Devary presented ISK new technology dealing with “personalized ImmunoOncology therapy” 

  • Molecular and Clinical Oncology Journal

New Article Published: Nerofe Phase I trial summary

11 Dec|Comments Off on New Article Published: Nerofe Phase I trial summary

The Phase I Nerofe (dTCApFs) human trial summary has been published in the Molecular and Clinical Oncology Journal.

In this trial Nerofe was found to be safe and well‑tolerated, and potentially efficacious as an anti-cancer agent.